Nordic Bioscience has developed biomarkers that target specific collagen subgroups associated with different subtypes of cancer-associated fibroblasts (CAFs).
During tumor progression, collagen fragments are released from the fibrotic tumor microenvironment into the bloodstream. Nordic Bioscience can detect these collagen fragments in the circulation using the Protein Fingerprint technology.
Nordic Bioscience's fibroblast and CAF biomarkers can quantify fibroblast and CAF activity, which are associated with prognosis and treatment response in cancer patients.
In addition, Nordic Bioscience's CAF biomarkers can identify collagen subgroups related to specific CAF subtypes. Such collagen subgroups are capable of identifying specific CAF subgroups and identifying patients with specific CAF subtypes.
CAF biomarkers can be used anywhere from target identification to pharmacodynamics to stratification of patients in clinical trials.
Visit our cancer biomarker portfolio and choose a panel that fits your clinical research or drug development targets!
Please don't hesitate to contact us if you have any questions or other inquiries.